Is Regular Radiographic Upper Urinary Tract Imaging for Surveillance of Non-Muscle Invasive Bladder Cancer Justified?
diagnostic imaging
surveillance
upper-urinary-tract urothelial cancer
urologic neoplasms
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Nov 2022
14 Nov 2022
Historique:
received:
03
10
2022
revised:
02
11
2022
accepted:
11
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Patients with non-muscle invasive (NMI) urothelial bladder cancer (BC) are at increased risk for the development of a secondary upper-urinary-tract urothelial carcinoma (UTUC). We aimed to assess the usefulness of routine upper-tract imaging surveillance during NMIBC follow-up in a patient cohort of a tertiary academic center. All routine upper-tract-imaging scans using computerized tomography urography (CTU) between 2003 and 2016 were assessed for UTUC detection. A total of 315 patients were analyzed. Initial tumor stage was Ta in 207 patients (65.7%), T1 in 98 patients (31.1%) and pure CIS in 10 patients (3.2%). A total of 149 (47.3%) presented with low-grade (LG), and 166 (52.7%) with high-grade (HG) disease. Median follow-up was 48 months (IQR: 55). Four patients (1.2%) were diagnosed with UTUC during follow-up. All four patients presented with initial Ta HG BC. Two of the patients (50%) were diagnosed by routine upper tract imaging. The other two patients were diagnosed after development of symptoms. The 5- and 10-year UTUC-free survival was 98.5% (standard error (SE) 0.9) and 97.6% (SE 1.3), respectively. UTUCs were detected exclusively in patients with initial HG disease, indicating that upper-tract surveillance might only be necessary in these patients.
Identifiants
pubmed: 36428679
pii: cancers14225586
doi: 10.3390/cancers14225586
pmc: PMC9688179
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Urol. 2013 Oct;190(4):1187-91
pubmed: 23680310
J Urol. 2010 Jan;183(1):48-55
pubmed: 19913253
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
Radiology. 2009 Feb;250(2):309-23
pubmed: 19188307
Indian J Urol. 2011 Apr;27(2):238-44
pubmed: 21814316
Crit Rev Oncol Hematol. 2003 Aug;47(2):155-69
pubmed: 12900009
Eur Radiol. 2008 Jan;18(1):4-17
pubmed: 17973110
Arch Intern Med. 2009 Dec 14;169(22):2078-86
pubmed: 20008690
Cancer Med. 2018 Aug;7(8):4098-4103
pubmed: 29953747
Urology. 1999 Jun;53(6):1144-8
pubmed: 10367843
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
PLoS One. 2014 Jan 07;9(1):e83192
pubmed: 24409280
AJR Am J Roentgenol. 2011 May;196(5):1102-9
pubmed: 21512076
Urol Oncol. 2018 Jun;36(6):306.e9-306.e15
pubmed: 29550096
J Urol. 1989 Jun;141(6):1311-3
pubmed: 2724427
J Urol. 2000 Oct;164(4):1183-7
pubmed: 10992362
Eur Urol. 2022 Jan;81(1):75-94
pubmed: 34511303
Bladder Cancer. 2016 Jan 7;2(1):27-36
pubmed: 27376122
J Clin Oncol. 1998 Mar;16(3):1099-102
pubmed: 9508196
Radiology. 1988 Jun;167(3):613-8
pubmed: 3363119
Urology. 2017 Feb;100:145-150
pubmed: 27765584
J Urol. 1998 Jul;160(1):45-8
pubmed: 9628602
Curr Opin Urol. 2019 May;29(3):189-197
pubmed: 30762673
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
BMJ. 2018 Jun 18;361:k2387
pubmed: 29914908
J Urol. 2006 Jan;175(1):74-7
pubmed: 16406874
J Clin Oncol. 2001 Jan 1;19(1):94-100
pubmed: 11134200
J Urol. 1999 Jun;161(6):1854-7
pubmed: 10332452